Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | BRAF | P15056 | 3/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838839 | 0.84 | ALDH1A1 (0.54) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL13329912 | 0.83 | KDR (0.46) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL2310333 | 0.82 | NPSR1 (0.56) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL2307693 | 0.81 | NR1H2 (0.50) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL1931675 | 0.80 | KDR (0.44) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL7115917 | 0.80 | SMO (0.44) | KDRLMNAHTTNPSR1 | |
| SCHEMBL580885 | 0.79 | KDR (0.62) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL2308828 | 0.79 | KDR (0.46) | KDRALDH1A1LMNAMAPTHTT | |
| SCHEMBL30773496 | 0.78 | FLT1 (0.59) | KDR | |
| SCHEMBL905518 | 0.78 | FLT1 (0.59) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| CN-101405282-B | Aurora kinase modulators and methods of use | AMGEN INC | 2015-03-25 | — | — | CN | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| CN-101405282-A | Aurora kinase modulators and methods of use | AMGEN INC (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | KDR 1017/4885ALDH1A1 2864/4885LMNA 620/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | KDR 682/4885ALDH1A1 1645/4885LMNA 637/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | KDR 1017/4885ALDH1A1 2864/4885LMNA 620/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | KDR 1017/4885ALDH1A1 2864/4885LMNA 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.